Cargando…
Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation
There are five active prostanoid metabolites of arachidonic acid (AA) that have widespread and varied physiologic functions throughout the body, including regulation of gastrointestinal mucosal blood flow, renal haemodynamics and primary haemostasis. Each prostanoid has at least one distinct recepto...
Autores principales: | Kirkby Shaw, Kristin, Rausch‐Derra, Lesley C., Rhodes, Linda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645826/ https://www.ncbi.nlm.nih.gov/pubmed/29067176 http://dx.doi.org/10.1002/vms3.13 |
Ejemplares similares
-
A Prospective, Randomized, Masked, Placebo‐Controlled Multisite Clinical Study of Grapiprant, an EP4 Prostaglandin Receptor Antagonist (PRA), in Dogs with Osteoarthritis
por: Rausch‐Derra, L., et al.
Publicado: (2016) -
Grapiprant: A snapshot of the current knowledge
por: Sartini, Irene, et al.
Publicado: (2021) -
Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor
por: Carlson, Noel G, et al.
Publicado: (2009) -
Quantification of Grapiprant and Its Stability Testing under Changing Environmental Conditions
por: Gumułka, Paweł, et al.
Publicado: (2022) -
A novel prostaglandin E receptor 4 (EP4) small molecule antagonist induces articular cartilage regeneration
por: Jin, Yunyun, et al.
Publicado: (2022)